Aurobindo Pharma and CSIR collaborate to develop vaccines against COVID-19
Capital MarketThe Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma announced a collaboration to develop vaccines to protect against SARS-CoV-2, also known as COVID-19.
Under the signed agreement between CSIR-Centre for Cellular and Molecular Biology (CCMB) and
Aurobindo Pharma, Aurobindo will partner with CSIR for development of several novel COVID-19 vaccines.
Three CSIR labs namely CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and
Indian Institute of Chemical Biology (IICB), Kolkata are developing vaccine candidates using different
technology platforms. Aurobindo will undertake clinical development and commercialization of the
vaccines.
Apart from this collaboration, Aurobindo is already developing a vaccine for SARS COV-2 through its wholly
owned US subsidiary Auro Vaccines. The SARS COV-2 vaccine candidate is based on the company's
proprietary replication-competent, attenuated, recombinant vesicular stomatitis (VSV, VesiculoVax)
vaccine delivery platform.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
